Fiona Rutherford

@Fi_Rutherford Fiona Rutherford is a journalist at Bloomberg. She covers health, pharmaceuticals and consumer goods industries.

Biography:  https://www.bloomberg.com/authors/ATkNo11cclo/fiona-rutherford

61%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author has a mixed reputation for journalistic standards. It is advisable to fact-check, scrutinize for bias, and check for conflicts of interest before relying on the author's reporting.

Bias

50%

Examples:

  • The author uses selective reporting to only mention that Walgreens sold $992 million worth of Cencora Inc. shares in February without disclosing any other details about this sale or how it affected their earnings.

Conflicts of Interest

50%

Examples:

  • The author does not mention any conflicts of interest in this article.

Contradictions

85%

Examples:

  • The company lowered the high end of its full-year adjusted earnings outlook in part due to a challenging retail environment in the U.S.
  • Walgreens Boots Alliance Inc. narrowed its fiscal 2024 guidance even as the drugstore chain beat Wall Street estimates for second-quarter profit and revenue.

Deceptions

75%

Examples:

  • The title implies something unexpected has happened at Walgreens when nothing out of the ordinary has occurred.
  • Walgreens Boots Alliance Inc. narrowed its fiscal 2024 guidance even as the drugstore chain beat Wall Street estimates for second-quarter profit and revenue.

Recent Articles

Walgreens Boots Alliance reports $6 billion net loss in Q2 due to VillageMD decline

Walgreens Boots Alliance reports $6 billion net loss in Q2 due to VillageMD decline

Broke On: Thursday, 28 March 2024 Walgreens Boots Alliance, Inc. reported a steep net loss for the fiscal second quarter of 2024 due to a $6 billion charge related to its investment in VillageMD's decline in value. Despite closing dozens of clinics and financial struggles, Walgreens sees VillageMD as critical to its transformation from drugstore chain into health care company. Meanwhile, Walgreens U.S retail pharmacy segment generated strong sales with an almost 5% increase from the same period last year.